A prognostic model for survival after salvage treatment with FLAG‐Ida +/− gemtuzumab‐ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
- 26 April 2016
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 174 (5) , 700-710
Abstract
Summary: The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony‐stimulating factor (FLAG‐Ida) is widely used in relapsed/refractory acute myeloid leukaemia (AML). We retrospectively analysed the results of 259 adult AML patients treated as first salvage with FLAG‐Ida or FLAG‐Ida plus Gentuzumab‐Ozogamicin (FLAGO‐Ida) of the Programa Español de Tratamientos en Hematología (PETHEMA) database, developing a prognostic score system of survival in this setting (SALFLAGE score). Overall, 221 patients received FLAG‐Ida and 38 FLAGO‐Ida; 92 were older than 60 years. The complete remission (CR)/CR with incomplete blood count recovery (CRi) rate was 51%, with 9% of induction deaths. Three covariates were associated with lower CR/CRi: high‐risk cytogenetics and t(8;21) at diagnosis, no previous allogeneic stem cell transplantation (allo‐SCT) and relapse‐free interval FLT3‐internal tandem duplication, length of relapse‐free interval and previous allo‐SCT. Using this stratification system, three groups were defined: favourable (26% of patients), intermediate (29%) and poor‐risk (45%), with an expected 5‐year OS of 52%, 26% and 7%, respectively. The SALFLAGE score discriminated a subset of patients with an acceptable long‐term outcome using FLAG‐Ida/FLAGO‐Ida regimen. The results of this retrospective analysis should be validated in independent external cohorts.Keywords
Funding Information
- Junta de Extremadura
- Fundación Española de Hematología (FEHH)
- Red Temática de Investigación Cooperativa en Cáncer (RD12/0036/0014)
This publication has 29 references indexed in Scilit:
- A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS studyLeukemia, 2011
- FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypeHaematologica, 2011
- Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapseHaematologica, 2010
- The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid LeukemiaJournal of Korean Medical Science, 2009
- Continuous infusion of intermediate‐dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: A prospective, multicenter phase II studyAmerican Journal of Hematology, 2008
- Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2008
- IDA-FLAG Regimen for the Therapy of Primary Refractory and Relapse Acute Leukemia: A Single-Center ExperienceAmerican Journal of Therapeutics, 2006
- Outcome of patients with acute myelogenous leukemia after second salvage therapyCancer, 2005
- Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2005
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003